A short duration multi-center study of RT001 in patients with Lateral Canthal Lines

Trial Profile

A short duration multi-center study of RT001 in patients with Lateral Canthal Lines

Discontinued
Phase of Trial: Phase II

Latest Information Update: 13 Jun 2016

At a glance

  • Drugs Botulinum toxin A (Primary)
  • Indications Facial-wrinkles
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jun 2016 Status changed from planning to discontinued, according to a Revance Therapeutics media release.
    • 13 Jun 2016 According to a Revance Therapeutics media release, based on the disappointing results of the phase II REALISE-1 trial (see CT profile 700245010), the company has decided to disontinue the development of RT001 topical for crow's feet. Based on these results, they company has also decided not to pursue the current clinical development plan for RT001 in axillary hyperhidrosis.
    • 22 Jun 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top